{"id":"fludeoxyglucose-f-18","_fda":{"id":"41abd652-7741-45e9-89a8-535a91d57f51","set_id":"08044d8f-036c-4809-997f-dd5180feebe6","openfda":{"nui":["N0000177914","N0000000205"],"unii":["0Z5B2CJX4D"],"route":["INTRAVENOUS"],"spl_id":["41abd652-7741-45e9-89a8-535a91d57f51"],"brand_name":["Fludeoxyglucose F-18"],"spl_set_id":["08044d8f-036c-4809-997f-dd5180feebe6"],"package_ndc":["65857-150-30"],"product_ndc":["65857-150"],"generic_name":["FLUDEOXYGLUCOSE F-18"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["FLUDEOXYGLUCOSE F-18"],"pharm_class_epc":["Radioactive Diagnostic Agent [EPC]"],"pharm_class_moa":["Radiopharmaceutical Activity [MoA]"],"manufacturer_name":["Cardinal Health 414, LLC"],"application_number":["ANDA203603"],"is_original_packager":[true]},"version":"8","pregnancy":["8.1 Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with Fludeoxyglucose F-18 Injection. It is also not known whether Fludeoxyglucose F-18 Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Consider alternative diagnostic tests in a pregnant woman; administer Fludeoxyglucose F-18 Injection only if clearly needed."],"references":["15 REFERENCES 1. Gallagher B.M., Ansari A., Atkins H., Casella V., Christman D.R., Fowler J.S., Ido T., MacGregor R.R., Som P., Wan C.N., Wolf A.P., Kuhl D.E., and Reivich M. “Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals,” J Nucl Med , 1977; 18, 990-6. 2. Jones S.C., Alavi, A., Christman D., Montanez, I., Wolf, A.P., and Reivich M. “The radiation dosimetry of 2 [F-18] fluoro-2-deoxy-D-glucose in man,” J Nucl Med , 1982; 23, 613-617. 3. Kocher, D.C. “Radioactive Decay Tables: A handbook of decay data for application to radiation dosimetry and radiological assessments,” 1981, DOE/TIC-I 1026, 89. 4. ICRP Publication 53, Volume 18, No. l-4,1987, pages 75-76."],"description":["11 DESCRIPTION 11.1 Chemical Characteristics Fludeoxyglucose F-18 Injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient 2-deoxy-2-[ 18 F]fluoro-D-glucose has the molecular formula of C 6 H 11 18 FO 5 with a molecular weight of 181.26, and has the following chemical structure: Fludeoxyglucose F-18 Injection is provided as a ready to use sterile, pyrogen free, clear, colorless citrate buffered solution. Each mL contains between 0.74 - 18.5 GBq (20 - 500 mCi/mL) of 2-deoxy-2-[ 18 F]fluoro-D-glucose at the EOS, 4.5 mg of sodium chloride in citrate buffer. The pH of the solution is between 4.5 and 7.5. The solution is packaged in a multiple-dose glass vial and does not contain any preservative. Chemical Structure 11.2 Physical Characteristics Fluorine F-18 has a physical half-life of 109.7 minutes and decays to Oxygen O-18 (stable) by positron decay. The principal photons useful for imaging are the dual 511 keV “annihilation” gamma photons that are produced and emitted simultaneously in opposite directions when the positron interacts with an electron (Table 2). Table 2. Principal Radiation Emission Data for Fluorine F-18 Radiation/Emission % Per Disintegration Mean Energy * Produced by positron annihilation From: Kocher, D.C. Radioactive Decay Tables DOE/TIC-I 1026, 89 (1981) Positron(β+) 96.73 249.8 keV Gamma(±)* 193.46 511.0 keV The specific gamma ray constant (point source air kerma coefficient) for fluorine F-18 is 5.7 R/hr/mCi (1.35 x 10 -6 Gy/hr/kBq) at 1 cm. The half-value layer (HVL) for the 511 keV photons is 4 mm lead (Pb) or 2.9 mm tungsten (W) alloy. The range of attenuation coefficients for this radionuclide as a function of shield thickness is shown in Table 3. For example, the interposition of an 8 mm thickness of Pb or 5.8 mm thickness of W alloy, with a coefficient of attenuation of 0.25, will decrease the external radiation by 75%. Table 3. Radiation Attenuation of 511 keV Photons by Lead (Pb) and Tungsten (W) Alloy Shielding Shield Thickness (Pb) mm Shield Thickness (W) Alloy mm Coefficient of Attenuation 0 0 0.00 4 2.9 0.50 8 5.8 0.25 13 9.4 0.10 26 18.7 0.01 39 27.6 0.001 52 37.4 0.0001 For use in correcting for physical decay of this radionuclide, the fractions remaining at selected intervals after calibration are shown in Table 4. Table 4. Physical Decay Chart for Fluorine F-18 Minutes Fraction Remaining * calibration time 0* 1.000 15 0.909 30 0.826 60 0.683 110 0.500 220 0.250 440 0.060"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Fludeoxyglucose F-18 Injection is supplied in a multi-dose, capped 30 mL glass vial containing between 0.74 - 18.5 GBq (20 - 500 mCi/mL), of no carrier added 2-deoxy-2-[F-18] fluoro-D-glucose, at end of synthesis, in approximately 2 - 30 mL. The contents of each vial are sterile, pyrogen-free and preservative-free. NDC 65857-150-30 0.74 - 18.5 GBq (20 - 500 mCi/mL) Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements for the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate. Store the Fludeoxyglucose F-18 Injection vial upright in a lead or tungsten alloy shielded container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). The expiration date and time are provided on the container label. Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS time."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Fludeoxyglucose F-18 Injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. In pediatric patients with epilepsy, the recommended dose is 2.6 mCi. The optimal dose adjustment on the basis of body size or weight has not been determined. In the oncology or cardiology settings, the safety and effectiveness of Fludeoxyglucose F-18 Injection have not been established in pediatric patients."],"effective_time":"20201204","nursing_mothers":["8.3 Nursing Mothers It is not known whether Fludeoxyglucose F-18 Injection is excreted in human milk. Consider alternative diagnostic tests in women who are breast-feeding. Use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if Fludeoxyglucose F-18 Injection is administered to a woman who is breast-feeding."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Oncology The efficacy of Fludeoxyglucose F-18 Injection in positron emission tomography cancer imaging was demonstrated in 16 independent studies. These studies prospectively evaluated the use of Fludeoxyglucose F-18 in patients with suspected or known malignancies, including non-small cell lung cancer, colo-rectal, pancreatic, breast, thyroid, melanoma, Hodgkin's and non-Hodgkin's lymphoma, and various types of metastatic cancers to lung, liver, bone, and axillary nodes. All these studies had at least 50 patients and used pathology as a standard of truth. The Fludeoxyglucose F-18 Injection doses in the studies ranged from 200 MBq to 740 MBq with a median and mean dose of 370 MBq. In the studies, the diagnostic performance of Fludeoxyglucose F-18 Injection varied with the type of cancer, size of cancer, and other clinical conditions. False negative and false positive scans were observed. Negative Fludeoxyglucose F-18 Injection PET scans do not exclude the diagnosis of cancer. Positive Fludeoxyglucose F-18 Injection PET scans cannot replace pathology to establish a diagnosis of cancer. Non-malignant conditions such as fungal infections, inflammatory processes and benign tumors have patterns of increased glucose metabolism that may give rise to false-positive scans. The efficacy of Fludeoxyglucose F-18 Injection PET imaging in cancer screening was not studied. 14.2 Cardiology The efficacy of Fludeoxyglucose F-18 Injection for cardiac use was demonstrated in ten independent, prospective studies of patients with coronary artery disease and chronic left ventricular systolic dysfunction who were scheduled to undergo coronary revascularization. Before revascularization, patients underwent PET imaging with Fludeoxyglucose F-18 Injection (74 - 370 MBq, 2 - 10 mCi) and perfusion imaging with other diagnostic radiopharmaceuticals. Doses of Fludeoxyglucose F-18 Injection ranged from 74 - 370 MBq (2 - 10 mCi). Segmental, left ventricular, wall-motion assessments of asynergic areas made before revascularization were compared in a blinded manner to assessments made after successful revascularization to identify myocardial segments with functional recovery. Left ventricular myocardial segments were predicted to have reversible loss of systolic function if they showed Fludeoxyglucose F-18 accumulation and reduced perfusion (i.e., flow-metabolism mismatch). Conversely, myocardial segments were predicted to have irreversible loss of systolic function if they showed reductions in both Fludeoxyglucose F-18 accumulation and perfusion (i.e., matched defects). Findings of flow-metabolism mismatch in a myocardial segment may suggest that successful revascularization will restore myocardial function in that segment. However, false-positive tests occur regularly, and the decision to have a patient undergo revascularization should not be based on PET findings alone. Similarly, findings of a matched defect in a myocardial segment may suggest that myocardial function will not recover in that segment, even if it is successfully revascularized. However, false-negative tests occur regularly, and the decision to recommend against coronary revascularization, or to recommend a cardiac transplant, should not be based on PET findings alone. The reversibility of segmental dysfunction as predicted with Fludeoxyglucose F-18 PET imaging depends on successful coronary revascularization. Therefore, in patients with a low likelihood of successful revascularization, the diagnostic usefulness of PET imaging with Fludeoxyglucose F-18 Injection is more limited. 14.3 Neurology In a prospective, open label trial, Fludeoxyglucose F-18 Injection was evaluated in 86 patients with epilepsy. Each patient received a dose of Fludeoxyglucose F-18 Injection in the range of 185-370 MBq (5-10 mCi). The mean age was 16.4 years (range: 4 months - 58 years; of these, 42 patients were less than 12 years and 16 patients were less than 2 years old). Patients had a known diagnosis of complex partial epilepsy and were under evaluation for surgical treatment of their seizure disorder. Seizure foci had been previously identified on ictal EEGs and sphenoidal EEGs. Fludeoxyglucose F-18 Injection PET imaging confirmed previous diagnostic findings in 16% (14/87) of the patients; in 34% (30/87) of the patients, Fludeoxyglucose F-18 Injection PET images provided new findings. In 32% (27/87), imaging with Fludeoxyglucose F-18 Injection was inconclusive. The impact of these imaging findings on clinical outcomes is not known. Several other studies comparing imaging with Fludeoxyglucose F-18 Injection results to subsphenoidal EEG, MRI and/or surgical findings supported the concept that the degree of hypometabolism corresponds to areas of confirmed epileptogenic foci. The safety and effectiveness of Fludeoxyglucose F-18 Injection to distinguish idiopathic epileptogenic foci from tumors or other brain lesions that may cause seizures have not been established."],"pharmacodynamics":["12.2 Pharmacodynamics Fludeoxyglucose F-18 Injection is rapidly distributed to all organs of the body after intravenous administration. After background clearance of Fludeoxyglucose F-18 Injection, optimal PET imaging is generally achieved between 30 to 40 minutes after administration. In cancer, the cells are generally characterized by enhanced glucose metabolism partially due to (1) an increase in activity of glucose transporters, (2) an increased rate of phosphorylation activity, (3) a reduction of phosphatase activity, or (4) a dynamic alteration in the balance among all these processes. However, glucose metabolism of cancer as reflected by Fludeoxyglucose F-18 accumulation shows considerable variability. Depending on tumor type, stage, and location, Fludeoxyglucose F-18 accumulation may be increased, normal, or decreased. Also, inflammatory cells can have the same variability of uptake of Fludeoxyglucose F-18. In the heart, under normal aerobic conditions, the myocardium meets the bulk of its energy requirements by oxidizing free fatty acids. Most of the exogenous glucose taken up by the myocyte is converted into glycogen. However, under ischemic conditions, the oxidation of free fatty acids decreases, exogenous glucose becomes the preferred myocardial substrate, glycolysis is stimulated, and glucose taken up by the myocyte is metabolized immediately instead of being converted into glycogen. Under these conditions, phosphorylated Fludeoxyglucose F-18 accumulates in the myocyte and can be detected with PET imaging. In the brain, cells normally rely on aerobic metabolism. In epilepsy, the glucose metabolism varies. Generally, during a seizure, glucose metabolism increases. Interictally, the seizure focus tends to be hypometabolic."],"pharmacokinetics":["12.3 Pharmacokinetics Distribution: In four healthy male volunteers, receiving an intravenous administration of 30 seconds in duration, the arterial blood level profile for Fludeoxyglucose F-18 decayed triexponentially. The effective half-life ranges of the three phases were 0.2-0.3 minutes, 10-13 minutes with a mean and standard deviation (STD) of 11.6 (±) 1.1 min, and 80-95 minutes with a mean and STD of 88 (±) 4 min. Plasma protein binding of Fludeoxyglucose F-18 has not been studied. Metabolism: Fludeoxyglucose F-18 is transported into cells and phosphorylated to [ 18 F]-FDG-6- phosphate at a rate proportional to the rate of glucose utilization within that tissue. [F-18]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[F-18]fluoro-6-phospho-D-mannose([F-18]FDM-6-phosphate). Fludeoxyglucose F-18 Injection may contain several impurities (e.g., 2-deoxy-2-chloro-D-glucose (ClDG)). Biodistribution and metabolism of ClDG are presumed to be similar to Fludeoxyglucose F-18 and would be expected to result in intracellular formation of 2-deoxy-2-chloro-6-phospho-D-glucose (ClDG-6-phosphate) and 2-deoxy-2-chloro-6-phospho-D-mannose (ClDM-6-phosphate). The phosphorylated deoxyglucose compounds are dephosphorylated and the resulting compounds (FDG, FDM, ClDG, and ClDM) presumably leave cells by passive diffusion. Fludeoxyglucose F-18 and related compounds are cleared from non-cardiac tissues within 3 to 24 hours after administration. Clearance from the cardiac tissue may require more than 96 hours. Fludeoxyglucose F-18 that is not involved in glucose metabolism in any tissue is then excreted in the urine. Elimination: Fludeoxyglucose F-18 is cleared from most tissues within 24 hours and can be eliminated from the body unchanged in the urine. Three elimination phases have been identified in the reviewed literature. Within 33 minutes, a mean of 3.9% of the administrated radioactive dose was measured in the urine. The amount of radiation exposure of the urinary bladder at two hours post-administration suggests that 20.6% (mean) of the radioactive dose was present in the bladder. Special Populations: The pharmacokinetics of Fludeoxyglucose F-18 Injection have not been studied in renally-impaired, hepatically impaired or pediatric patients. Fludeoxyglucose F-18 is eliminated through the renal system. Avoid excessive radiation exposure to this organ system and adjacent tissues. The effects of fasting, varying blood sugar levels, conditions of glucose intolerance, and diabetes mellitus on Fludeoxyglucose F-18 distribution in humans have not been ascertained [ see Warnings and Precautions ( 5.2 ) ]."],"adverse_reactions":["6 ADVERSE REACTIONS Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available. Hypersensitivity reactions have occurred; have emergency resuscitation equipment and personnel immediately available ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Cardinal Health at 1-800-618-2768 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS None None ( 4 )"],"description_table":["
Table 2. Principal Radiation Emission Data for Fluorine F-18
Radiation/Emission% Per DisintegrationMean Energy
* Produced by positron annihilation From: Kocher, D.C. Radioactive Decay Tables DOE/TIC-I 1026, 89 (1981)
Positron(β+)96.73249.8 keV
Gamma(±)*193.46511.0 keV
","
Table 3. Radiation Attenuation of 511 keV Photons by Lead (Pb) and Tungsten (W) Alloy Shielding
Shield Thickness (Pb) mmShield Thickness (W) Alloy mmCoefficient of Attenuation
000.00
42.90.50
85.80.25
139.40.10
2618.70.01
3927.60.001
5237.40.0001
","
Table 4. Physical Decay Chart for Fluorine F-18
MinutesFraction Remaining
* calibration time
0*1.000
150.909
300.826
600.683
1100.500
2200.250
4400.060
"],"drug_interactions":["7 DRUG INTERACTIONS The possibility of interactions of Fludeoxyglucose F-18 Injection with other drugs taken by patients undergoing PET imaging has not been studied."],"mechanism_of_action":["12.1 Mechanism of Action Fludeoxyglucose F-18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F-18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [ 18 F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F-18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F-18 transport and phosphorylation (expressed as the ''lumped constant'' ratio), Fludeoxyglucose F-18 is used to assess glucose metabolism. In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F-18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F-18 reflect greater than normal rates of glucose metabolism."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Fludeoxyglucose F-18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F-18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [ 18 F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F-18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F-18 transport and phosphorylation (expressed as the ''lumped constant'' ratio), Fludeoxyglucose F-18 is used to assess glucose metabolism. In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F-18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F-18 reflect greater than normal rates of glucose metabolism. 12.2 Pharmacodynamics Fludeoxyglucose F-18 Injection is rapidly distributed to all organs of the body after intravenous administration. After background clearance of Fludeoxyglucose F-18 Injection, optimal PET imaging is generally achieved between 30 to 40 minutes after administration. In cancer, the cells are generally characterized by enhanced glucose metabolism partially due to (1) an increase in activity of glucose transporters, (2) an increased rate of phosphorylation activity, (3) a reduction of phosphatase activity, or (4) a dynamic alteration in the balance among all these processes. However, glucose metabolism of cancer as reflected by Fludeoxyglucose F-18 accumulation shows considerable variability. Depending on tumor type, stage, and location, Fludeoxyglucose F-18 accumulation may be increased, normal, or decreased. Also, inflammatory cells can have the same variability of uptake of Fludeoxyglucose F-18. In the heart, under normal aerobic conditions, the myocardium meets the bulk of its energy requirements by oxidizing free fatty acids. Most of the exogenous glucose taken up by the myocyte is converted into glycogen. However, under ischemic conditions, the oxidation of free fatty acids decreases, exogenous glucose becomes the preferred myocardial substrate, glycolysis is stimulated, and glucose taken up by the myocyte is metabolized immediately instead of being converted into glycogen. Under these conditions, phosphorylated Fludeoxyglucose F-18 accumulates in the myocyte and can be detected with PET imaging. In the brain, cells normally rely on aerobic metabolism. In epilepsy, the glucose metabolism varies. Generally, during a seizure, glucose metabolism increases. Interictally, the seizure focus tends to be hypometabolic. 12.3 Pharmacokinetics Distribution: In four healthy male volunteers, receiving an intravenous administration of 30 seconds in duration, the arterial blood level profile for Fludeoxyglucose F-18 decayed triexponentially. The effective half-life ranges of the three phases were 0.2-0.3 minutes, 10-13 minutes with a mean and standard deviation (STD) of 11.6 (±) 1.1 min, and 80-95 minutes with a mean and STD of 88 (±) 4 min. Plasma protein binding of Fludeoxyglucose F-18 has not been studied. Metabolism: Fludeoxyglucose F-18 is transported into cells and phosphorylated to [ 18 F]-FDG-6- phosphate at a rate proportional to the rate of glucose utilization within that tissue. [F-18]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[F-18]fluoro-6-phospho-D-mannose([F-18]FDM-6-phosphate). Fludeoxyglucose F-18 Injection may contain several impurities (e.g., 2-deoxy-2-chloro-D-glucose (ClDG)). Biodistribution and metabolism of ClDG are presumed to be similar to Fludeoxyglucose F-18 and would be expected to result in intracellular formation of 2-deoxy-2-chloro-6-phospho-D-glucose (ClDG-6-phosphate) and 2-deoxy-2-chloro-6-phospho-D-mannose (ClDM-6-phosphate). The phosphorylated deoxyglucose compounds are dephosphorylated and the resulting compounds (FDG, FDM, ClDG, and ClDM) presumably leave cells by passive diffusion. Fludeoxyglucose F-18 and related compounds are cleared from non-cardiac tissues within 3 to 24 hours after administration. Clearance from the cardiac tissue may require more than 96 hours. Fludeoxyglucose F-18 that is not involved in glucose metabolism in any tissue is then excreted in the urine. Elimination: Fludeoxyglucose F-18 is cleared from most tissues within 24 hours and can be eliminated from the body unchanged in the urine. Three elimination phases have been identified in the reviewed literature. Within 33 minutes, a mean of 3.9% of the administrated radioactive dose was measured in the urine. The amount of radiation exposure of the urinary bladder at two hours post-administration suggests that 20.6% (mean) of the radioactive dose was present in the bladder. Special Populations: The pharmacokinetics of Fludeoxyglucose F-18 Injection have not been studied in renally-impaired, hepatically impaired or pediatric patients. Fludeoxyglucose F-18 is eliminated through the renal system. Avoid excessive radiation exposure to this organ system and adjacent tissues. The effects of fasting, varying blood sugar levels, conditions of glucose intolerance, and diabetes mellitus on Fludeoxyglucose F-18 distribution in humans have not been ascertained [ see Warnings and Precautions ( 5.2 ) ]."],"indications_and_usage":["1 INDICATIONS AND USAGE Fludeoxyglucose F-18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F-18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: • Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer ( 1 ). • Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging ( 1 ). • Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures ( 1 ). 1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 Cardiology For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. 1.3 Neurology For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Radiation risks: use smallest dose necessary for imaging ( 5.1 ). • Blood glucose abnormalities: may cause suboptimal imaging ( 5.2 ). 5.1 Radiation Risks Radiation-emitting products, including Fludeoxyglucose F-18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [ see Dosage and Administration ( 2.5 ) ]. 5.2 Blood Glucose Abnormalities In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F-18 Injection administration."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been performed to evaluate the Fludeoxyglucose F-18 Injection carcinogenic potential, mutagenic potential or effects on fertility."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Instruct patients in procedures that increase renal clearance of radioactivity. Encourage patients to: • drink water or other fluids (as tolerated) in the 4 hours before their PET study. • void as soon as the imaging study is completed and as often as possible thereafter for at least one hour. Manufactured and Distributed by: Cardinal Health 414, LLC 7000 Cardinal Place Dublin, OH 43017"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Fludeoxyglucose F-18 Injection emits radiation. Use procedures to minimize radiation exposure. Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [ see Description ( 11.2 ) ]. Fludeoxyglucose F-18 Injection emits radiation. Use procedures to minimize radiation exposure. Screen for blood glucose abnormalities. • In the oncology and neurology settings, instruct patients to fast for 4 – 6 hours prior to the drug’s injection. Consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to the drug’s administration ( 5.2 ). • In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 – 75 grams) prior to the drug’s injection facilitates localization of cardiac ischemia ( 2.3 ). Aseptically withdraw Fludeoxyglucose F-18 Injection from its container and administer by intravenous injection ( 2 ). The recommended dose: • for adults is 5 – 10 mCi (185 – 370 MBq), in all indicated clinical settings ( 2.1 ). • for pediatric patients is 2.6 mCi in the neurology setting ( 2.2 ). Initiate imaging within 40 minutes following drug injection; acquire static emission images 30 – 100 minutes from time of injection ( 2 ). 2.1 Recommended Dose for Adults Within the oncology, cardiology and neurology settings, the recommended dose for adults is 5 – 10 mCi (185 – 370 MBq) as an intravenous injection. 2.2 Recommended Dose for Pediatric Patients Within the neurology setting, the recommended dose for pediatric patients is 2.6 mCi, as an intravenous injection. The optimal dose adjustment on the basis of body size or weight has not been determined [ see Use in Special Populations ( 8.4 ) ]. 2.3 Patient Preparation • To minimize the radiation absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to drink water or other fluids (as tolerated) in the 4 hours before their PET study. • Encourage the patient to void as soon as the imaging study is completed and as often as possible thereafter for at least one hour. • Screen patients for clinically significant blood glucose abnormalities by obtaining a history and/or laboratory tests [ see Warnings and Precautions ( 5.2 ) ]. Prior to Fludeoxyglucose F-18 PET imaging in the oncology and neurology settings, instruct patient to fast for 4 – 6 hours prior to the drug’s injection. • In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 – 75 grams) prior to Fludeoxyglucose F-18 Injection facilitates localization of cardiac ischemia. 2.4 Radiation Dosimetry The estimated human absorbed radiation doses (rem/mCi) to a newborn (3.4 kg), 1-year old (9.8 kg), 5-year old (19 kg), 10-year old (32 kg), 15-year old (57 kg), and adult (70 kg) from intravenous administration of Fludeoxyglucose F-18 Injection are shown in Table 1. These estimates were calculated based on human 2 data and using the data published by the International Commission on Radiological Protection 4 for Fludeoxyglucose 18 F. The dosimetry data show that there are slight variations in absorbed radiation dose for various organs in each of the age groups. These dissimilarities in absorbed radiation dose are due to developmental age variations (e.g., organ size, location, and overall metabolic rate for each age group). The identified critical organs (in descending order) across all age groups evaluated are the urinary bladder, heart, pancreas, spleen, and lungs. Table 1. Estimated Absorbed Radiation Doses (rem/mCi) After Intravenous Administration of Fludeoxyglucose F-18 Injection a Organ Newborn (3.4 kg) 1-year old (9.8 kg) 5-year old (19 kg) 10-year old (32 kg) 15-year old (57 kg) Adult (70 kg) a MIRDOSE 2 software was used to calculate the radiation absorbed dose. Assumptions on the biodistribution based on data from Gallagher et al. 1 and Jones et al. 2 b The dynamic bladder model with a uniform voiding frequency of 1.5 hours was used. * LLI = lower large intestine; ** ULI = upper large intestine Bladder wall b 4.3 1.7 0.93 0.60 0.40 0.32 Heart wall 2.4 1.2 0.70 0.44 0.29 0.22 Pancreas 2.2 0.68 0.33 0.25 0.13 0.096 Spleen 2.2 0.84 0.46 0.29 0.19 0.14 Lungs 0.96 0.38 0.20 0.13 0.092 0.064 Kidneys 0.81 0.34 0.19 0.13 0.089 0.074 Ovaries 0.80 0.8 0.19 0.11 0.058 0.053 Uterus 0.79 0.35 0.19 0.12 0.076 0.062 LLI wall* 0.69 0.28 0.15 0.097 0.060 0.051 Liver 0.69 0.31 0.17 0.11 0.076 0.058 Gallbladder wall 0.69 0.26 0.14 0.093 0.059 0.049 Small intestine 0.68 0.29 0.15 0.096 0.060 0.047 ULI wall** 0.67 0.27 0.15 0.090 0.057 0.046 Stomach wall 0.65 0.27 0.14 0.089 0.057 0.047 Adrenals 0.65 0.28 0.15 0.095 0.061 0.048 Testes 0.64 0.27 0.14 0.085 0.052 0.041 Red marrow 0.62 0.26 0.14 0.089 0.057 0.047 Thymus 0.61 0.26 0.14 0.086 0.056 0.044 Thyroid 0.61 0.26 0.13 0.080 0.049 0.039 Muscle 0.58 0.25 0.13 0.078 0.049 0.039 Bone surface 0.57 0.24 0.12 0.079 0.052 0.041 Breast 0.54 0.22 0.11 0.068 0.043 0.034 Skin 0.49 0.20 0.10 0.060 0.037 0.030 Brain 0.29 0.13 0.09 0.078 0.072 0.070 Other tissues 0.59 0.25 0.13 0.083 0.052 0.042 2.5 Radiation Safety – Drug Handling • Use waterproof gloves, effective radiation shielding, and appropriate safety measures when handling Fludeoxyglucose F-18 Injection to avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel and other persons. • Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides. • Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [ see Description ( 11.2 ) ]. • The dose of Fludeoxyglucose F-18 used in a given patient should be minimized consistent with the objectives of the procedure, and the nature of the radiation detection devices employed. 2.6 Drug Preparation and Administration • Calculate the necessary volume to administer based on calibration time and dose. • Aseptically withdraw Fludeoxyglucose F-18 Injection from its container. • Inspect Fludeoxyglucose F-18 Injection visually for particulate matter and discoloration before administration, whenever solution and container permit. • Do not administer the drug if it contains particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations. • Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS. 2.7 Imaging Guidelines • Initiate imaging within 40 minutes following Fludeoxyglucose F-18 Injection administration. • Acquire static emission images 30 – 100 minutes from the time of injection."],"spl_product_data_elements":["Fludeoxyglucose F-18 Fludeoxyglucose F-18 FLUDEOXYGLUCOSE F-18 FLUDEOXYGLUCOSE F-18 SODIUM CHLORIDE DISODIUM CITRATE SESQUIHYDRATE TRISODIUM CITRATE DIHYDRATE WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Multiple-dose glass vial containing 0.74 - 18.5 GBq (20 - 500 mCi/mL) of Fludeoxyglucose F-18 Injection and 4.5 mg of sodium chloride in citrate buffer (approximately 2 - 30 mL volume) for intravenous administration. Multiple-dose glass vial containing 0.74 - 18.5 GBq (20 - 500 mCi/mL) of Fludeoxyglucose F-18 Injection and 4.5 mg of sodium chloride in citrate buffer (approximately 2 - 30 mL volume) for intravenous administration ( 3 )."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Pregnancy Category C: No human or animal data. Consider alternative diagnostics; use only if clearly needed ( 8.1 ). • Nursing mothers: Use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if Fludeoxyglucose F-18 Injection is administered to a woman who is breast-feeding ( 8.3 ). • Pediatric Use: Safety and effectiveness in pediatric patients have not been established in the oncology and cardiology settings ( 8.4 ). 8.1 Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with Fludeoxyglucose F-18 Injection. It is also not known whether Fludeoxyglucose F-18 Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Consider alternative diagnostic tests in a pregnant woman; administer Fludeoxyglucose F-18 Injection only if clearly needed. 8.3 Nursing Mothers It is not known whether Fludeoxyglucose F-18 Injection is excreted in human milk. Consider alternative diagnostic tests in women who are breast-feeding. Use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if Fludeoxyglucose F-18 Injection is administered to a woman who is breast-feeding. 8.4 Pediatric Use The safety and effectiveness of Fludeoxyglucose F-18 Injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. In pediatric patients with epilepsy, the recommended dose is 2.6 mCi. The optimal dose adjustment on the basis of body size or weight has not been determined. In the oncology or cardiology settings, the safety and effectiveness of Fludeoxyglucose F-18 Injection have not been established in pediatric patients."],"dosage_and_administration_table":["
Table 1. Estimated Absorbed Radiation Doses (rem/mCi) After Intravenous Administration of Fludeoxyglucose F-18 Injectiona
OrganNewborn (3.4 kg)1-year old (9.8 kg)5-year old (19 kg)10-year old (32 kg)15-year old (57 kg)Adult (70 kg)
a MIRDOSE 2 software was used to calculate the radiation absorbed dose. Assumptions on the biodistribution based on data from Gallagher et al.1 and Jones et al.2 b The dynamic bladder model with a uniform voiding frequency of 1.5 hours was used. * LLI = lower large intestine; ** ULI = upper large intestine
Bladder wallb4.31.70.930.600.400.32
Heart wall2.41.20.700.440.290.22
Pancreas2.20.680.330.250.130.096
Spleen2.20.840.460.290.190.14
Lungs0.960.380.200.130.0920.064
Kidneys0.810.340.190.130.0890.074
Ovaries0.800.80.190.110.0580.053
Uterus0.790.350.190.120.0760.062
LLI wall*0.690.280.150.0970.0600.051
Liver0.690.310.170.110.0760.058
Gallbladder wall0.690.260.140.0930.0590.049
Small intestine0.680.290.150.0960.0600.047
ULI wall**0.670.270.150.0900.0570.046
Stomach wall0.650.270.140.0890.0570.047
Adrenals0.650.280.150.0950.0610.048
Testes0.640.270.140.0850.0520.041
Red marrow0.620.260.140.0890.0570.047
Thymus0.610.260.140.0860.0560.044
Thyroid0.610.260.130.0800.0490.039
Muscle0.580.250.130.0780.0490.039
Bone surface0.570.240.120.0790.0520.041
Breast0.540.220.110.0680.0430.034
Skin0.490.200.100.0600.0370.030
Brain0.290.130.090.0780.0720.070
Other tissues0.590.250.130.0830.0520.042
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 20-500 mCi/mL Vial Label 20-500 mCi/mL Vial Label NDC # 65857-150-30 30 mL Multiple-Dose Vial Fludeoxyglucose F-18 Injection, USP 20 mCi/mL to 500 mCi/mL @ EOS* Sterile, Non-pyrogenic Date: / / Exp: / / Time: : CAUTION: RADIOACTIVE MATERIAL Each mL Contains: 0.74 GBq to 18.5 GBq (20 mCi/mL to 500 mCi/mL) of no-carrier added Fludeoxyglucose F-18 (2-deoxy-2- [ 18 F]fluoro-D-glucose) @ EOS*; 4.5 mg of sodium chloride in citrate buffer. Do not use if cloudy or if it contains particulate matter. Activity @ EOS* mCi Diagnostic - For Intravenous Use Only Lot #: (Expires 12 hours after EOS*) Store at 25°C (77°F) (see insert) Store upright in a shielded container. Aseptically withdraw and handle doses. [ 18 F] Half-Life = 109.7 min Calculate correct dosage from date and time of calibration. *EOS = End of Synthesis Mfg by Cardinal Health 414, LLC-Dublin, OH 43017 Rx ONLY Principal Display Panel - 20-500 mCi/mL Vial"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been performed to evaluate the Fludeoxyglucose F-18 Injection carcinogenic potential, mutagenic potential or effects on fertility."]},"safety":{"boxedWarnings":[],"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLUDEOXYGLUCOSE F 18","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:58:57.249130+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:59:07.669245+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUDEOXYGLUCOSE F 18","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:59:08.429962+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:58:55.138917+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:58:55.138959+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:59:58.802421+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:58:55.138965+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Fludeoxyglucose F-18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F-18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [ 18 F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-p","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:59:29.751335+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2030434/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:59:09.452428+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available. Hypersensitivity reactions have occurred; have emergency resuscitation equipment and personnel immediately available ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Cardinal Health at 1-800-618-2768 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:59:32.992218+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203603","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:58:55.138968+00:00"}},"_dailymed":{"setId":"5d05df4a-463e-4e66-9387-f3a842e20cd0","title":"FLUDEOXYGLUCOSE F 18 (FLUDEOXYGLUCOSE F-18) INJECTION, SOLUTION [JUBILANT DRAXIMAGE INC., DBA JUBILANT RADIOPHARMA]"},"mechanism":{"target":"glucose transporter proteins, hexokinase, glucose-6-phosphatase","drugClass":"Radioactive Diagnostic Agent [EPC]","explanation":"Fludeoxyglucose F-18 mimics glucose and is taken up by cells that use glucose for energy. It is transported into cells via glucose transporters and phosphorylated by hexokinase, trapping it inside the cell until dephosphorylated. The amount retained reflects the cell's metabolic rate.","oneSentence":"Fludeoxyglucose F-18 is a glucose analog that accumulates in cells with high glucose metabolism, reflecting metabolic activity.","technicalDetail":"Fludeoxyglucose F-18 is transported into cells by facilitative glucose transporter proteins and phosphorylated by hexokinase to form [18F]FDG-6-phosphate. This phosphorylated form cannot exit the cell until dephosphorylated by glucose-6-phosphatase. The balance of these processes determines the retention and clearance of Fludeoxyglucose F-18."},"_scrapedAt":"2026-03-27T23:46:38.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T06:59:59.189264+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"fludeoxyglucose-f-18-oncology---malignancy-evaluati","name":"Oncology - Malignancy Evaluation","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer","diagnosticRequired":null,"brandNameForIndication":""},{"id":"fludeoxyglucose-f-18-cardiology---myocardial-metabo","name":"Cardiology - Myocardial Metabolism","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with coronary artery disease and left ventricular dysfunction","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with coronary artery disease and left ventricular dysfunction","diagnosticRequired":"Myocardial perfusion imaging","brandNameForIndication":""},{"id":"fludeoxyglucose-f-18-neurology---epileptic-seizures","name":"Neurology - Epileptic Seizures","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with foci of epileptic seizures","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with foci of epileptic seizures","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04569591","phase":"NA","title":"DDAVP for Pituitary Adenoma","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-03-09","conditions":"Cushing's Disease, Pituitary Adenoma","enrollment":22},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":"Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma","enrollment":70},{"nctId":"NCT02193425","phase":"EARLY_PHASE1","title":"Reliability of the Human Brain Connectome","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2015-06-08","conditions":"Normal Physiology","enrollment":112},{"nctId":"NCT04533750","phase":"PHASE1","title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-20","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT01934660","phase":"","title":"Links Between Inflammation and Cardiometabolic Diseases","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-12-02","conditions":"Diabetes Mellitus, Cardiovascular Disease, Healthy Volunteer","enrollment":150},{"nctId":"NCT06465017","phase":"NA","title":"ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer","status":"TERMINATED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-01-04","conditions":"Tumor, Solid Tumor, Thyroid Cancer","enrollment":149},{"nctId":"NCT06503146","phase":"PHASE2","title":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-09","conditions":"Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma","enrollment":320},{"nctId":"NCT04214262","phase":"PHASE3","title":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-13","conditions":"Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":480},{"nctId":"NCT05286801","phase":"PHASE1, PHASE2","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-17","conditions":"Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma","enrollment":86},{"nctId":"NCT07494162","phase":"NA","title":"Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-04","conditions":"Myofascial Pain Syndrome (MPS), Chronic Low-back Pain (cLBP)","enrollment":64},{"nctId":"NCT04943211","phase":"PHASE3","title":"Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging","status":"RECRUITING","sponsor":"Anna Raciborska","startDate":"2021-04-01","conditions":"Histiocytosis","enrollment":150},{"nctId":"NCT05756270","phase":"","title":"Clinical Applicability of pCASL as a Substitute for FDG-PET in MCI and SCD Patients","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2022-06-03","conditions":"Mild Cognitive Impairment, Subjective Cognitive Decline","enrollment":150},{"nctId":"NCT03683355","phase":"","title":"Characterization of RadiOlabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves.","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-11-09","conditions":"Infective Endocarditis","enrollment":30},{"nctId":"NCT00006421","phase":"","title":"Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-10-25","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT04316117","phase":"PHASE2","title":"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-09-15","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":138},{"nctId":"NCT07487883","phase":"","title":"Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-15","conditions":"Non-Small Cell Lung Cancer, Malignant Neoplasm, Pulmonary Nodules","enrollment":80},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma","enrollment":252},{"nctId":"NCT04804371","phase":"NA","title":"Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-04","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT07479095","phase":"NA","title":"Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2025-07-03","conditions":"Lepidic-Predominant Lung Adenocarcinoma, Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT05191940","phase":"NA","title":"Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2022-05-16","conditions":"Pancreas Cancer","enrollment":30},{"nctId":"NCT07482072","phase":"","title":"Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-03","conditions":"Alzheimer Dementia (AD), Diabete Type 2","enrollment":60},{"nctId":"NCT05931302","phase":"NA","title":"Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2023-11-16","conditions":"Lobular Breast Carcinoma","enrollment":40},{"nctId":"NCT04143516","phase":"PHASE2, PHASE3","title":"Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-10-25","conditions":"Liver Metastases","enrollment":200},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT06144853","phase":"","title":"The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2024-03-15","conditions":"Peritoneal Cancer, Peritoneal Metastases, Peritoneal Carcinomatosis","enrollment":34},{"nctId":"NCT07471776","phase":"PHASE2","title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-03-11","conditions":"Metastatic Breast Cancer ( HER2 Negative)","enrollment":45},{"nctId":"NCT00194298","phase":"","title":"FDG-PET Imaging in Complicated Diabetic Foot","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2002-10","conditions":"Diabetic Foot Disease","enrollment":240},{"nctId":"NCT00194285","phase":"","title":"FDG-PET Imaging in Painful Joint Prosthesis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2001-03","conditions":"Painful Joint Prostheses","enrollment":530},{"nctId":"NCT04812080","phase":"NA","title":"EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-08-18","conditions":"Healthy Volunteers From Racial/Ethnic Minority Populations","enrollment":20},{"nctId":"NCT07463300","phase":"","title":"A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Lung Cancer","enrollment":5500},{"nctId":"NCT05876858","phase":"EARLY_PHASE1","title":"EXPLORER Total Body PET/CT Imaging for Myofascial Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2023-06-13","conditions":"Myofascial Pain","enrollment":53},{"nctId":"NCT05160480","phase":"","title":"A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Davis","startDate":"2024-06-07","conditions":"Prostate Cancer, Breast Cancer, Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT04478318","phase":"NA","title":"Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2020-06-01","conditions":"Lung Neoplasm, Lymphoma, Melanoma","enrollment":180},{"nctId":"NCT04020978","phase":"NA","title":"Parametric PET of Genitourinary Cancer","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2019-07-16","conditions":"Genitourinary Cancer","enrollment":11},{"nctId":"NCT04841707","phase":"NA","title":"Total-Body Parametric 18F-FDG PET of COVID-19","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-05-10","conditions":"Covid19","enrollment":13},{"nctId":"NCT06014515","phase":"EARLY_PHASE1","title":"Single-tracer Multiparametric PET Imaging","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2024-02-14","conditions":"Healthy Subjects, Cardiovascular Disease","enrollment":60},{"nctId":"NCT02379377","phase":"PHASE1","title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-15","conditions":"Adult Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma, Cholangiocarcinoma","enrollment":110},{"nctId":"NCT07458906","phase":"NA","title":"DLL3-Targeted PET/CT in Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-12-01","conditions":"DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer","enrollment":60},{"nctId":"NCT04454450","phase":"NA","title":"Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-06-22","conditions":"Ovarian Cancer, High Grade Ovarian Serous","enrollment":10},{"nctId":"NCT07454096","phase":"PHASE4","title":"Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2026-04-30","conditions":"Cardiac Disease, Device Related Infection","enrollment":200},{"nctId":"NCT03853915","phase":"NA","title":"FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-23","conditions":"Cervical Cancer","enrollment":64},{"nctId":"NCT07442292","phase":"","title":"PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02","conditions":"Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma (Skin Cancer)","enrollment":40},{"nctId":"NCT07004673","phase":"","title":"18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-12","conditions":"Carotid Artery Plaque, Ischemic Stroke, PET / MR","enrollment":100},{"nctId":"NCT07448727","phase":"","title":"Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT","status":"RECRUITING","sponsor":"University of Rome Tor Vergata","startDate":"2024-11-20","conditions":"Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT05321316","phase":"NA","title":"Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-05-31","conditions":"Urothelial Carcinoma","enrollment":20},{"nctId":"NCT05976763","phase":"PHASE3","title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-10-20","conditions":"Mantle Cell Lymphoma","enrollment":421},{"nctId":"NCT07449858","phase":"","title":"18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-07-01","conditions":"Non Small Cell Lung Cancer","enrollment":500},{"nctId":"NCT05436093","phase":"NA","title":"CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2022-06-23","conditions":"Solid Tumor","enrollment":15},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT06502691","phase":"PHASE1, PHASE2","title":"[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-02-26","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":22},{"nctId":"NCT05710328","phase":"PHASE2","title":"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-05-10","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma","enrollment":235},{"nctId":"NCT07443696","phase":"PHASE2","title":"PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2025-12-18","conditions":"Ischemic Cardiomyopathy, Heart Failure","enrollment":40},{"nctId":"NCT04667585","phase":"NA","title":"Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx","status":"RECRUITING","sponsor":"Duke University","startDate":"2021-04-12","conditions":"Oropharynx Cancer","enrollment":120},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT06814587","phase":"","title":"Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-07-01","conditions":"Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)","enrollment":15},{"nctId":"NCT06103838","phase":"PHASE2","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-25","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":60},{"nctId":"NCT02125786","phase":"PHASE2","title":"A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-07","conditions":"Ependymoma","enrollment":68},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT07430475","phase":"","title":"Utility of 18F-FDG PET/CT for Suspected Infection in the Inpatient Setting: a Single Centre Retrospective Cohort Study","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2022-01-04","conditions":"Fever of Unknown Origin, Inflammation of Unknown Origin, Fever","enrollment":266},{"nctId":"NCT07431255","phase":"","title":"Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2026-03-01","conditions":"Alzheimer Disease (AD)","enrollment":35},{"nctId":"NCT07419867","phase":"PHASE2","title":"A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT03507257","phase":"","title":"Longitudinal Early-onset Alzheimer's Disease Study Protocol","status":"RECRUITING","sponsor":"Indiana University","startDate":"2018-04-30","conditions":"Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment","enrollment":850},{"nctId":"NCT05647564","phase":"NA","title":"PET/CT Characterization of Treatment Resistance","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-06","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT06820957","phase":"PHASE2, PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":"CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma","enrollment":437},{"nctId":"NCT02226276","phase":"NA","title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-01-07","conditions":"Bone Metastases, HER2-positive Breast Cancer, Liver Metastases","enrollment":10},{"nctId":"NCT07285993","phase":"PHASE2","title":"Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET","status":"NOT_YET_RECRUITING","sponsor":"Randy Yeh","startDate":"2026-02-16","conditions":"Breast Cancer, Metastatic Invasive Lobular Breast Cancer","enrollment":15},{"nctId":"NCT06335914","phase":"NA","title":"Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-04-03","conditions":"Advanced Prostate Cancer","enrollment":30},{"nctId":"NCT04016818","phase":"EARLY_PHASE1","title":"Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-06","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05775939","phase":"NA","title":"PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-20","conditions":"Lung Carcinoma, Esophageal Carcinoma","enrollment":20},{"nctId":"NCT05121012","phase":"","title":"Synaptic Loss in Multiple System Atrophy","status":"RECRUITING","sponsor":"University of Exeter","startDate":"2021-09-01","conditions":"Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)","enrollment":36},{"nctId":"NCT04273555","phase":"PHASE1, PHASE2","title":"Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-01","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT04359732","phase":"NA","title":"Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRI","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2020-05-08","conditions":"Esophageal Cancer, Esophageal Neoplasms","enrollment":121},{"nctId":"NCT01237054","phase":"PHASE2","title":"Imaging in MGUS, SMM and MM","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-17","conditions":"Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance","enrollment":31},{"nctId":"NCT06175390","phase":"PHASE2","title":"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2024-03-27","conditions":"Triple Negative Breast Cancer","enrollment":81},{"nctId":"NCT04459273","phase":"PHASE1","title":"Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-08-27","conditions":"Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma","enrollment":26},{"nctId":"NCT07178587","phase":"NA","title":"Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-02-02","conditions":"Hepatocellular Carcinoma (HCC), Gastro-Entero-Pancreatic Tumors (GEPs)","enrollment":28},{"nctId":"NCT06083103","phase":"","title":"Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)","status":"RECRUITING","sponsor":"Centre Paul Strauss","startDate":"2023-10-12","conditions":"Cervical Cancer","enrollment":50},{"nctId":"NCT07366710","phase":"NA","title":"Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-05","conditions":"Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)","enrollment":36},{"nctId":"NCT06500065","phase":"NA","title":"68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-09-30","conditions":"Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT06836726","phase":"PHASE2","title":"Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-05-27","conditions":"Castration Resistant Prostate Cancer","enrollment":35},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT04692103","phase":"PHASE2","title":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-10","conditions":"Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7","enrollment":2},{"nctId":"NCT06225505","phase":"NA","title":"Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2026-01-05","conditions":"Triple Negative Breast Cancer","enrollment":450},{"nctId":"NCT04251481","phase":"NA","title":"Diffusion MRI for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-10-16","conditions":"Head Cancer Neck","enrollment":16},{"nctId":"NCT06297902","phase":"NA","title":"RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-08-19","conditions":"Head and Neck Cancer, Radiotherapy Side Effect","enrollment":100},{"nctId":"NCT03173924","phase":"PHASE2","title":"18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-06","conditions":"Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer","enrollment":96},{"nctId":"NCT03181867","phase":"PHASE2","title":"18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-03","conditions":"Prostate Neoplasms, Prostatic Cancer, Prostate Cancer","enrollment":800},{"nctId":"NCT06199713","phase":"","title":"Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-01-30","conditions":"Melanoma, Melanoma Stage III, Melanoma Stage IV","enrollment":24},{"nctId":"NCT07353554","phase":"NA","title":"Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-02-01","conditions":"Multiple Myeloma (MM)","enrollment":30},{"nctId":"NCT07313033","phase":"NA","title":"[68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-03-30","conditions":"Lobular Carcinoma, Breast Cancer","enrollment":45},{"nctId":"NCT07097363","phase":"PHASE2","title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-12-07","conditions":"B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":18},{"nctId":"NCT04333537","phase":"PHASE2, PHASE3","title":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2020-09-23","conditions":"Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma","enrollment":686}],"_emaApprovals":[],"_faersSignals":[{"count":20,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":16,"reaction":"DRUG INEFFECTIVE"},{"count":13,"reaction":"OFF LABEL USE"},{"count":10,"reaction":"NEUTROPENIA"},{"count":10,"reaction":"WRONG PRODUCT ADMINISTERED"},{"count":9,"reaction":"NAUSEA"},{"count":8,"reaction":"PRODUCT LABEL ON WRONG PRODUCT"},{"count":7,"reaction":"DEATH"},{"count":7,"reaction":"HYPOTENSION"},{"count":7,"reaction":"RASH MACULO-PAPULAR"}],"administration":{"route":"Intravenous"},"crossReferences":{"chemblId":"CHEMBL2030434"},"_approvalHistory":[{"date":"20150407","type":"ORIG","sponsor":"PRECISION NUCLEAR","applicationNumber":"ANDA204546"},{"date":"20141029","type":"ORIG","sponsor":"TRUSTEES UNIV PA","applicationNumber":"ANDA203801"},{"date":"20200103","type":"SUPPL","sponsor":"BRIGHAM WOMENS","applicationNumber":"ANDA203816"},{"date":"20141030","type":"ORIG","sponsor":"BRIGHAM WOMENS","applicationNumber":"ANDA203816"},{"date":"20171227","type":"SUPPL","sponsor":"PHARMALOGIC","applicationNumber":"ANDA204264"},{"date":"20141218","type":"ORIG","sponsor":"PHARMALOGIC","applicationNumber":"ANDA204264"},{"date":"20200103","type":"SUPPL","sponsor":"PETNET","applicationNumber":"ANDA079086"},{"date":"20111027","type":"SUPPL","sponsor":"PETNET","applicationNumber":"ANDA079086"},{"date":"20110225","type":"ORIG","sponsor":"PETNET","applicationNumber":"ANDA079086"}],"publicationCount":135,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"FLUDEOXYGLUCOSE F 18","genericName":"FLUDEOXYGLUCOSE F 18","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1994","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T06:59:59.189264+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}